Dr. Sharmeen Bhuiyan
Sylhet Medical Univesrity
This article examines what Bangladesh’s newly revived liver transplant program means for patients, for health investment priorities, and for the fairness of concentrating resources on one terminal disease while others remain underserved.
The story reads like an ordinary hospital case until the numbers sink in. A Dhaka homemaker with liver cirrhosis had her family pricing an Indian transplant at roughly fifty lakh taka, feeling unreachable despite years of worsening illness. Instead, she became the first patient treated when Bangladesh Medical University revived the procedure, with her son donating part of his liver. She recovered at a fraction of the cost abroad. Multiply that by six, the transplants BMU has performed since last September, and a genuinely new institutional capability emerges.
Why the Demand Is Larger Than Six Cases Suggest
The scale of unmet need dwarfs what has been treated so far. BMU’s hepatology department says around five crore Bangladeshis live with liver disease, with twenty-two to twenty-five thousand annual deaths, mostly from cirrhosis or cancer. Roughly a thousand patients need a transplant yearly.
Against that backdrop, six procedures mark a beginning, not a solution. A country that performed transplants only sporadically since 2010, with long gaps between isolated cases, has now built its first repeatable pathway, one BMU intends to run at roughly two a month.
The Financial Case for Investing at Home
The economics are stark enough to justify attention on their own terms. Treatment abroad, once travel, accommodation, and hospital charges are added up, can reach roughly one crore taka. BMU’s domestic procedure, once it moves to a paid model, is expected to cost thirty to thirty-five lakh, and the featured family paid only about ten lakh even under the current free arrangement. That gap is not marginal. It is the difference between an operation reserved for the wealthy few and one that becomes plausible for a much wider population, particularly with government subsidy.
There is also a longer-term logic beyond individual families. Money currently leaving the country for treatment in India, Thailand, or Singapore represents outbound capital a domestic program could retain, alongside the expertise and revenue that come with scale. The involvement of nineteen departments and senior hepatobiliary surgeons suggests an institutional knowledge base that, if sustained, would not need indefinite reliance on outside technical support of the kind BMU received from Hyderabad for this first cohort.
A Single Disease Getting Attention While Others Wait
The harder question is one of fairness. Liver disease is a genuine crisis, but far from the only terminal condition Bangladeshi patients face without adequate local options. Kidney failure, advanced pediatric and rare cancers, congenital heart conditions, and bone marrow transplants for blood cancers all face similarly thin domestic infrastructure, often forcing families into the same impossible arithmetic.
Seen against this wider field, concentrating specialist training, coordination, and subsidy on liver transplantation alone raises a legitimate equity concern. Why does one terminal illness receive a flagship program while others, statistically comparable in mortality, remain dependent on medical tourism or informal fundraising through social media and mosque announcements. There is no evidence this came at another program’s direct expense, but resource allocation in a system with limited specialist manpower is rarely neutral. Every hepatobiliary surgeon trained in time and capacity is not spent building equivalent capability elsewhere.
Weighing Concentration Against Momentum
There is a reasonable counterargument, however. Complex transplant medicine benefits from concentration rather than dispersion in its early stages. A single center building genuine expertise in one procedure, assembling a multidisciplinary team, and refining protocols across dozens of cases is more likely to produce reliable outcomes than several under-resourced programs attempting the same procedure simultaneously.
Once liver transplantation is established as a routine, safely repeatable service in Bangladesh, the institutional knowledge, training pipeline, and administrative model it creates could plausibly be extended to other transplant programs, much as successful kidney transplant expertise elsewhere has sometimes preceded liver programs. Framed this way, the current focus is not necessarily a permanent inequity but a demonstration project that other specialties could eventually follow.
What the Health Ministry Should Do Next
For that more optimistic reading to hold, the Health Ministry needs clear intent. It should publish a transparent, multiyear roadmap naming which additional conditions, kidney failure, pediatric cancer, cardiac disease, will receive comparable investment and by what timeline. It should establish predictable public subsidy criteria rather than case by case funding, so access does not depend on which hospital a patient reaches. It should also build training pipelines sharing BMU’s expertise with other public hospitals, and pair clinical investment with organ donation campaigns, since transplant programs depend on donor availability as much as surgical skill.
The recovery described at the start of this piece is a genuine achievement. Whether it becomes the first chapter of a fairer health system, or a well-publicized exception, depends on the choices the Health Ministry makes next.
